Pleural mesothelioma: Experience with 62 cases in 9 years;Mesotelioma pleural: Experiencia durante 9 años y descripción de 62 casos

Archivos de Bronconeumologia

Volumn 40, Issue 5, 2004, Pages 203-208

  Villena Garrido, V ^a   Lopez Encuentra A ^a   Echave Sustaeta, J ^a   Alvarez Martinez C ^a   Rey Terron L ^a   Sotelo, M T ^a   Ballestin C ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Malignant pleural effusion; Mesothelioma; Pleural biopsy; Survival

Indexed keywords

ASBESTOS; LACTATE DEHYDROGENASE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DYSPNEA; EXPERIENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; PH; PLEURA BIOPSY; PLEURA EFFUSION; PLEURA FLUID; PLEURA THICKENING; PROGNOSIS; RADIODIAGNOSIS; SURVIVAL; SURVIVAL RATE; THORACOSCOPY; THORACOTOMY; THORAX PAIN; THROMBOCYTE COUNT;

EID: 2542429239     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13060344     Document Type: Article

References (40)

1. Peto J, Hodgson JT, Mathews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995;345:535-9.
2. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999;79:666-72.
3. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997;145:211-8.
4. Cárcoba Alonso A. Informe sobre el amianto en España. En: Cárcoba AC, editor. El amianto en España. Madrid: Ediciones GPS, 2000; p. 17-55.
5. López Encuentra A, Varela Simó G, Sotelo Rodríguez T. Mesoteliomas pleurales malignos. Descripción de 23 casos con análisis de supervivencia. Rev Clin Esp 1987;181:496-502.
6. Narváez Rodríguez I, Candela Maestú M, Domínguez Platas T, Entrenas Costa LM, Antona Gómez JM, Checa Pinilla JM, et al. Mesotelioma pleural: revisión de 10 años. Neumosur 1992;1:23-7.
7. Grupo de Estudio del mesotelioma en Barcelona (GEMEBA). Mortalidad por mesotelioma pleural en la provincia de Barcelona. Med Clin (Barc) 1993;101:565-9.
8. Mesía R, Pallares C, Mendoza L, Bellet M, Vega M, León C, et al. Mesotelioma maligno pleural. Características clínicas, factores pronósticos y tratamiento. Arch Bronconeumol 1995;31:455-9.
9. Montero Martínes C, Yebra Pimentel MT, Bouso Montero M, Blanco Aparicio M, Veres Racaamonde A, Otero González I, et al. Mesotelioma difuso maligno: aportación de 23 casos. Rev Clin Esp 1998;198:665-8.
10. García Prim JM, López Perales M, Moreno Balsalobre R, Prados Sánchez MC, Saldaña Garrido D, Bravo Bravo JL. Mesotelioma pleural en la Comunidad de Madrid. Neumomadrid-PAR 1999;2(Supl):146-7.
11. Villena V, Nieto Barbero A. Derrame pleural. En: Martín Escribano P, López Encuentra A, editores. Pautas de práctica clínica en neumología. Madrid: Idepsa, 1996; p. 58-67.
12. Ruffie P, Feld R, Minkin S, Cormier Y, Boutan-Lazore A, Ginsberg R, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989;7:1157-68.
13. Teschke K, Morgan MS, Chekoway H, Franklin G, Spinelly JJ, Belle G, et al. Mesothelioma surveillance to locate sources of exposure of asbestos. Can J Public Health 1997;88:163-8.
14. García Prats MD, Ballestín C, Sotelo MT, López Encuentra A, Mayordomo JI. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumors. Histopathol 1998;32:462-72.
15. González Lois G, Ballestín C, Sotelo MT, López Ríos F, García Prats MD, Villena V. Combined use of novel epithelial (Moc-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. Histopathol 2001;38:528-34.
16. Light RW. Pleural diseases. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001.
17. Villena V, López Encuentra A, Echave-Sustaeta J, Martín Escribano P, Ortuño de Solo B, Estenoz Alfaro J. Diagnostic value of CA 72.4, carcinoembrionic antigen, CA 15.3 and CA 19.9 assay in pleural fluid: a study of 207 patients. Cancer 1996;78:736-40.
18. Miédougé M, Rouzaud P, Salama G, Pujazon MC, Vicent C, Mauduyt MA, et al. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer 1999;81:1059-65.
19. Ordóñez NG. Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol 1999;112:75-89.
20. Branscheid D, Krysa S, Bauer E, Bilzabruck H, Schirren J. Diagnostic and therapeutic strategy in malignant pleural mesothelioma. Eur J Cardio-Thorac Surg 1991;5:466-73.
21. Cantó A, Guijarro R, Arnau A, Galbis J, Martorell M, García Aguado R. Videothoracoscopy in the diagnosis and treatment of malignant pleural mesothelioma with associated pleural effusions. Thorac Cardiovasc Surg 1997;45:16-9.
22. Sterman DH, Kaiser LR, Albelda SM. Advances in the treatment of malignant pleural mesothelioma. Chest 1999;116:504-20.
23. Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002;38:111-21.
24. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-65.
25. Steele JPC. Prognostic factors in mesothelioma. Semin Oncol 2002;29:36-40.
26. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by cancer an leukemia group B. Chest 1998;113:723-31.
27. Boutin C, Rey F, Gouvemet J, Viallat JR, Astoul P, Ledoray V. Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients, part 2: prognosis and staging. Cancer 1993;72:394-404.
28. Curran D, Sahmoud T, Therasse P, Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research an Cancer experience. J Clin Oncol 1998;16:145-52.
29. De Pangher Manzini V, Brollo A, Francheschi S, De Matthaeis M, Talamini R, Bianchi C. Prognostic factors of malignant mesothelioma of the pleura. Cancer 1993;72:410-7.
30. Van Gelder T, Damhuis RAM, Hoogsteden HC. Prognostic factors and survival in malignant pleural mesothelioma. Eur Respir J 1994;7:1035-8.
31. Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Faber Cancer Institute and Brigham and Women's hospital experience over two decades, 1968-1985. J Clin Oncol 1988;6:147-53.
32. Tammilehto L. Malignant mesothelioma: prognostic factors in a prospective study of 98 patients. Lung Cancer 1992;8:175-84.
33. Calavrezos A, Koschel G, Husselmann H, Taylessani A, Heilman HP, Faber H, et al. Malignant mesothelioma of the pleura: a prospective study of 132 patients from 1981-1985. Klin Wochenschr 1988;66:607-13.
34. Sridhar KS, Doria R, Raub WA, Thurer RJ, Saldana M. New strategies are needed in diffuse malignant mesothelioma. Cancer 1992;70:2969-79.
35. Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van der Merwe CA. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988;6:527-35.
36. Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM. Diffuse malignant mesothelioma. Ann Intern Med 1982;96:746-55.
37. Schouwink H, Korse CM, Bonfrer JM, Hart AA, Baas P. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer 1999;25:25-32.
38. Spirtas R, Conelly RR, Tucker MA. Survival patterns for malignant mesothelioma:the SEER experience. Int J Cancer 1988;42:525-30.
39. Chailleux E, Dabuois G, Pioche D, Lajartre M, Lajartre AY, Rembeaux A, et al. Prognostic factors in diffuse malignant pleural mesothelioma. Chest 1988;93:159-62.
40. Gottehrer A, Taryle DA, Reed CE, Sahn SA. Pleural fluid analysis in malignant mesothelioma. Chest 1991;100:1003-6.